Lupin Gets US FDA Nod for Epilepsy Drug Brivaracetam Oral Solution; Watch Stock

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

Lupin Secures US FDA Approval for Epilepsy Drug, Eyes Major US Market Launch

Zydus Lifesciences Limited ने गुरुवार, 15 जनवरी को शेयर बाजारों को सूचित किया कि उसे US Food and Drug Administration (US FDA) से Eltrombopag Tablets के लिए अंतिम मंजूरी मिल गई है.

C

CNBC Awaaz•24-02-2026, 19:30

Lupin Secures US FDA Approval for Epilepsy Drug, Eyes Major US Market Launch

•Lupin Limited received US FDA approval for its epilepsy drug, Brivaracetam Oral Solution.
•The medication is used to treat epilepsy and is beneficial for patients with difficulty swallowing tablets.
•Lupin plans to launch the drug in the US market, targeting an annual turnover of approximately ₹1,230 crore.
•Experts believe this approval will strengthen Lupin's US portfolio and boost earnings and market share.
•This marks another significant step for Lupin in the US market, expanding its presence in the anti-epileptic segment.

Read Full Article on Cnbc in Hindi

✦

More like this

✦

More like this

Lupin said the US drug regulator has classified its inspection of the Pithampur Unit 2 manufacturing facility as 'official action indicated' (OAI).

The US Food and Drug Administration (USFDA) had conducted inspections at the facility from July 8 to July 17, 2025, and closed it by issuing Form 483 with four observations.

Lupin's Ankleshwar Facility Gets 2 US FDA Observations; Q3 Profit Up 37.5%

Lupin share price, Lupin stock, Lupin shares, Lupin Q3, Lupin Q3 earnings, Lupin Q3 results, Lupin brokerages, Lupin rating, Lupin target price, Lupin buy or sell, buy or sell Lupin, brokerage calls, Lupin stock analysis, Lupin Q3 earnings, Lupin target price, Lupin US sales, Lupin margin guidance, Lupin EPS growth, Lupin brokerage ratings

Lupin's Maharashtra Office Under GST Inspection; Shares Rise Amidst Strong Financials

Lupin Settles Mirabegron Patent Dispute with Astellas for $90 Million

Lupin Settles Mirabegron Patent Dispute with Astellas for $90 Million

Representational image (Image: News18)

Lupin's Goa Plant Receives Satisfactory EIR from USFDA

Lupin said the US drug regulator has classified its inspection of the Pithampur Unit 2 manufacturing facility as 'official action indicated' (OAI).

The US Food and Drug Administration (USFDA) had conducted inspections at the facility from July 8 to July 17, 2025, and closed it by issuing Form 483 with four observations.

Lupin Q3 Net Profit Jumps 38% on Strong US Sales, Divestment Gains

accumulate

Prabhudas Lilladher Recommends 'Accumulate' on Lupin, Sets Rs 2400 Target